Annovis Bio, Inc. Common Stock (NY:ANVS)

1.180 UNCHANGED

Delayed Quote Updated: 7:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Annovis Bio, Inc. Common Stock

< Previous 1 2

...

12 13 14 15 16 17 18 19 Next >

Why Is Biogen Pursuing a New Direction in Alzheimer's Research? ↗

August 13, 2021

It might be that Biogen, too, is abandoning the theory that amyloid plaque is the cause of the disease.

Via The Motley Fool

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Annovis Bio, Inc. (ANVS) on Behalf of Investors

August 05, 2021

From Law Offices of Howard G. Smith

Via Business Wire

ANNOVIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Annovis Bio, Inc. on Behalf of Annovis Stockholders and Encourages Investors to Contact the Firm

August 03, 2021

From Bragar Eagel & Squire, P.C.

Via Business Wire

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Annovis Bio, Inc. (ANVS) on Behalf of Investors

August 03, 2021

From Glancy Prongay & Murray LLP

Via Business Wire

The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal ↗

July 28, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 27) Bio-Rad Laboratories, Inc...

Via Benzinga

99 Biggest Movers From Yesterday ↗

August 06, 2021

Gainers Score Media and Gaming Inc. (NASDAQ: SCR) shares climbed 79.9% to close at $32.64 on Thursday after the company, and Penn National Gaming, announced they entered into a...

Via Benzinga

The Law Offices of Frank R. Cruz Announces Investigation of Annovis Bio, Inc. (ANVS) on Behalf of Investors

August 03, 2021

From The Law Offices of Frank R. Cruz

Via Business Wire

61 Biggest Movers From Yesterday ↗

August 03, 2021

Gainers Ever-Glory International Group, Inc. (NASDAQ: EVK) shares climbed 124.8% to close at $5.08 on Monday after the company announced a $5 million stock repurchase program....

Via Benzinga

INVESTOR ALERT: Kirby McInerney LLP Announces an Investigation of Shareholder Claims Against Annovis Bio, Inc.

August 02, 2021

From Kirby McInerney LLP

Via Business Wire

40 Stocks Moving In Monday's Mid-Day Session ↗

August 02, 2021

Gainers Ever-Glory International Group, Inc. (NASDAQ: EVK) shares jumped 133% to $5.27 after the company announced a $5 million stock repurchase program. Exicure, Inc. (NASDAQ:...

Via Benzinga

Here's Why Annovis Bio, Anavex Life Sciences, and Cassava Sciences Sank on Thursday ↗

July 29, 2021

A clinical-trial flop for Annovis Bio is reminding investors that developing new drugs for Alzheimer's disease is an extremely risky business.

Via The Motley Fool

63 Biggest Movers From Friday ↗

August 02, 2021

Gainers ERYTECH Pharma S.A. (NASDAQ: ERYP) shares surged 55% to close at $6.37 on Friday after the company said the FDA has granted its eryaspase fast track designation for the...

Via Benzinga

ANVS Stock: The Alzheimer’s Drug News That Has Annovis Bio Plunging Today ↗

July 29, 2021

Shares of ANVS stock are plummeting on Thursday after Annovis Bio reported weak results from two clinical trials for its leading drug.

Via InvestorPlace

The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs ↗

August 01, 2021

Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies. Most pharma majors reported strong quarterly results....

Via Benzinga

70 Biggest Movers From Yesterday ↗

July 30, 2021

Gainers Xenetic Biosciences, Inc. (NASDAQ: XBIO) shares surged 65.1% to settle at $5.30 on Thursday. Xenetic Biosciences recently reported closing of $12.5 million private...

Via Benzinga

Annovis Bio Shares Cut In Half Following Alzheimer's Data Presentation ↗

July 29, 2021

Annovis Bio, Inc. (NYSE: ANVS), which took off on a strong rally in January, has quickly lost most of the gains. What To Know: Annovis, a clinical-stage neurodegenerative diseases...

Via Benzinga

Mid-Day Market Update: LendingClub Surges Following Strong Q2 Results; Atreca Shares Plummet ↗

July 29, 2021

Midway through trading Thursday, the Dow traded up 0.55% to 35,122.75 while the NASDAQ rose 0.47% to 14,831.28. The S&P also rose, gaining 0.61% to 4,427.36. The U.S. has the...

Via Benzinga

Topics Stocks

44 Stocks Moving In Thursday's Mid-Day Session ↗

July 29, 2021

Gainers NanoVibronix, Inc. (NASDAQ: NAOV) shares jumped 47.6% to $2.8198 after the company announced it received registration approval for UroShield from TGA Australia....

Via Benzinga

Mid-Morning Market Update: Markets Open Higher; Mastercard Profit Beats Estimates ↗

July 29, 2021

Following the market opening Thursday, the Dow traded up 0.44% to 35,085.92 while the NASDAQ rose 0.27% to 14,802.51. The S&P also rose, gaining 0.45% to 4,420.49. The U.S....

Via Benzinga

Topics Stocks

Annovis Bio Stock Crashes After Much-Hyped Alzheimer's Drug Flops In Midstage Test ↗

July 29, 2021

Annovis Bio's Alzheimer's drug failed to significantly outperform the placebo in a midstage test, leading ANVS stock to plummet on Thursday.

Via Investor's Business Daily

28 Stocks Moving in Thursday's Pre-Market Session ↗

July 29, 2021

Gainers LendingClub Corporation (NYSE: LC) shares rose 44.6% to $23.49 in pre-market trading after the company reported better-than-expected Q2 results and raised guidance. Acer...

Via Benzinga

Why Annovis Stock Is Bucking The Trend In Alzheimer's — And Two Others To Watch ↗

July 23, 2021

Annovis bucked the trend depressing Alzheimer's stocks on Friday as ANVS stock touched a record high while SAVA stock and INMB stock fell.

Via Investor's Business Daily

Annovis Bio's Alzheimer's Candidate To Proceed Into Final Cohort Of Mid-Stage Study, Data Expected In 2022 ↗

July 20, 2021

Data Safety Monitoring Board (DSMB) has reviewed safety and tolerability data for Cohort 2 of Annovis Bio Inc's (NYSE: ANVS) Phase 2 Alzheimer's disease trial...

Via Benzinga

The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More ↗

July 25, 2021

Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism that was set in motion by the solid start...

Via Benzinga

Got $2,500? Check Out These 3 Alzheimer's Therapy Stocks ↗

July 17, 2021

Treating Alzheimer's is extremely difficult, but these innovative companies are taking a stab at it.

Via The Motley Fool

Here's Why The Biotech Stocks You Bought Keep Going Down ↗

July 17, 2021

Good news! There's a way to avoid this portfolio pain -- and it doesn't involve avoiding the whole sector.

Via The Motley Fool

Better Biotech Stock: Biogen vs. Annovis Bio ↗

July 16, 2021

Both are making Alzheimer's drugs, but only one can claim success as of today.

Via The Motley Fool

58 Biggest Movers From Yesterday ↗

July 13, 2021

Gainers MediaCo Holding Inc. (NASDAQ: MDIA) shares jumped 311.6% to close at $17.00 on Monday after jumping 20% on Friday. State Auto Financial Corporation (NASDAQ: STFC) shares...

Via Benzinga

38 Stocks Moving In Monday's Mid-Day Session ↗

July 12, 2021

Gainers State Auto Financial Corporation (NASDAQ: STFC) shares jumped 189.5% to $49.96 after the company agreed to be acquired by Liberty Mutual Insurance for $52 per share in...

Via Benzinga

Neurodegenerative Disease And Cancer Stocks Among Top Biotech Gainers In 2021 ↗

July 04, 2021

Biotech stocks underperformed the broader market in the first half of 2021, with the iShares Nasdaq Biotechnology ETF IBB advancing about 8% year-to-date compared to the roughly 14% gain for the S&P...

Via Talk Markets

Topics Stocks

< Previous 1 2

...

12 13 14 15 16 17 18 19 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.